Congress has advanced multiple bipartisan bills aimed at strengthening dementia research and improving early detection, paired with a $100 million funding increase for Alzheimer’s disease research through the National Institutes of Health in fiscal year 2026. The CHANGE Act, ASAP Act, and AADAPT Act represent a coordinated legislative effort to expand NIH funding, improve early assessment and diagnosis, authorize Medicare coverage for blood-based screening tests, and strengthen the dementia-trained workforce.
Combined with $41.5 million allocated for the CDC’s implementation of the BOLD Infrastructure for Alzheimer’s Act—bringing total annual federal dementia research funding to $3.9 billion—these measures signal that federal policymakers from both parties recognize dementia as a public health priority deserving sustained investment and systemic change. This article explores the specific bills advancing through Congress, explains how each addresses different gaps in dementia care and research, and shows what these legislative developments mean for patients, families, and healthcare providers. State-level progress in Texas and California demonstrates that momentum extends beyond Washington.
Table of Contents
- Which Bipartisan Bills Are Advancing Dementia Research Priorities?
- How Does Federal Funding Increase Support Research Goals?
- Why Do Early Detection and Diagnosis Bills Matter So Much?
- How Will the AADAPT Act Change What Primary Care Doctors Can Do?
- What State-Level Progress Shows About Momentum Beyond Congress
- What Does This Legislation Mean for Patients and Families?
- What Comes Next as Legislation Advances Through Congress?
- Conclusion
Which Bipartisan Bills Are Advancing Dementia Research Priorities?
The CHANGE Act (Concentrating on high Value Alzheimer’s Needs to Get to an End Act) has advanced unanimously out of the Ways and Means Committee with bipartisan support, positioning it as a near-term legislative achievement. This bill focuses specifically on improving early assessment and diagnosis of Alzheimer’s disease—a critical gap, since many people live with undiagnosed cognitive decline for years. The ASAP Act (Alzheimer’s Screening and Prevention) would authorize Medicare coverage for blood-based dementia screening tests, removing a significant financial barrier to early detection. Currently, Medicare does not routinely cover these newer blood biomarker tests despite their growing clinical validity, leaving many older adults unable to access them without out-of-pocket costs. The third major bill, the AADAPT Act (Accelerating Access to Dementia & Alzheimer’s Provider Training), was reintroduced in the House with bipartisan sponsorship and addresses a different but equally pressing problem: most primary care physicians receive minimal training in dementia diagnostics.
By equipping primary care providers with better diagnostic capabilities and resources, the AADAPT Act aims to catch dementia earlier in community settings where most patients first seek care. What distinguishes these bills is that they target different leverage points in the healthcare system rather than simply increasing research funding. The CHANGE Act and ASAP Act operate on the detection side, while AADAPT strengthens the provider workforce. However, none of these bills guarantees passage—they must still navigate the full congressional process, committee amendments, and floor votes. CHANGE Act’s unanimous committee advancement is encouraging, but committee advancement is not final passage.
How Does Federal Funding Increase Support Research Goals?
The $100 million increase in NIH funding for Alzheimer’s and dementia research represents an important signal of priority, but context matters for understanding its scope. The increase brings dedicated NIH dementia research funding to higher levels, while the separate $41.5 million for the CDC’s BOLD Infrastructure for Alzheimer’s Act implementation contributes to a total annual federal commitment now reaching $3.9 billion. That $3.9 billion figure spans multiple agencies and initiatives—NIH, CDC, and other federal health programs—rather than being a single pool of flexible research money. However, this aggregate funding level allows the federal government to support a broader portfolio of research from basic science (understanding Alzheimer’s disease mechanisms) to applied research (testing interventions) to public health infrastructure (surveillance and education).
The limitation here is that funding increases often focus on specific research priorities set by the administering agencies, meaning not all dementia research questions receive equal support. For example, frontotemporal dementia (FTD) and Lewy body dementia receive less research attention and funding than Alzheimer’s disease despite their devastating impact on younger patients and families. Additionally, the funding cycle takes time—appropriated dollars must be converted into funded grants, which then generate research results over years. Patients and families waiting for breakthrough treatments cannot wait for the research pipeline to produce answers, which is why early detection and symptom management remain critical in the near term.
Why Do Early Detection and Diagnosis Bills Matter So Much?
The CHANGE Act and ASAP Act prioritize early detection because catching Alzheimer’s disease in its earliest stages—even before symptoms fully emerge—has become scientifically possible and clinically meaningful. Blood biomarker tests can now identify Alzheimer’s pathology years before cognitive symptoms appear, offering a window for potential interventions. The problem is access: these tests are expensive, insurance coverage is inconsistent, and many primary care doctors are not yet trained to order or interpret them. By requiring Medicare coverage and standardizing early assessment protocols, these bills lower the barrier to diagnosis. Consider a 68-year-old woman who notices she’s forgetting names more often and whose family expresses concern. Under current systems, her primary care doctor might reassure her that some memory loss is normal with age and send her home.
With ASAP Act coverage, that same patient could access a blood test within her doctor’s office visit, potentially catching Alzheimer’s pathology decades before significant cognitive decline. The tradeoff, however, involves what happens after early diagnosis. Identifying disease does not currently mean a cure or a way to completely prevent progression—it means living with the knowledge that your brain shows Alzheimer’s pathology. For some patients and families, this knowledge is empowering and allows them to plan, pursue research trials, or make lifestyle changes. For others, it creates anxiety and a sense of hopelessness if no proven preventive treatment is available. The bills advance detection capability but do not, on their own, solve the complex ethical question of what patients should do with early diagnostic information.
How Will the AADAPT Act Change What Primary Care Doctors Can Do?
The AADAPT Act (Accelerating Access to Dementia & Alzheimer’s Provider Training) addresses a workforce gap that affects millions of older adults: most primary care physicians did not receive substantial training in dementia diagnosis and management during medical school or residency. The bill aims to strengthen that training pipeline by funding dementia education programs for primary care providers and helping them implement better diagnostic protocols. If fully funded and implemented, this means that when you visit your family doctor with memory concerns, they will have current knowledge of cognitive assessment tools, biomarker testing, and referral pathways rather than relying on outdated or incomplete knowledge. In rural areas where specialist neurologists are scarce, strengthening primary care capability becomes especially important—a small-town doctor becomes the first and sometimes only specialist a patient accesses.
A practical limitation is that passing a bill to authorize training is not the same as ensuring all primary care doctors receive that training quickly. Medical education changes slowly, residency programs must update curricula, and practicing physicians often do not have time or funding for new training during their careers. The AADAPT Act creates infrastructure and funding; adoption depends on individual healthcare systems and physician interest. Additionally, primary care doctors remain time-constrained. Even with better training, cognitive assessment takes time—blood biomarker tests save some time compared to formal neuropsychological testing, which is why the ASAP Act’s insurance coverage becomes important as a complementary change.
What State-Level Progress Shows About Momentum Beyond Congress
While Congress debates and advances bills at the federal level, states have already begun moving on their own dementia research and care initiatives. Texas passed Senate Bill 5, establishing the Dementia Prevention and Research Institute of Texas (DPRIT), signed into law in March 2025 with bipartisan support. DPRIT will coordinate dementia research efforts across Texas universities and medical centers, reducing duplication and accelerating discovery. California took a different approach, enacting SB 1047, which requires healthcare providers to report frontotemporal dementia diagnoses to improve tracking and research pathways. These state laws serve as a laboratory for dementia policy—they show that bipartisan support for dementia initiatives exists beyond Washington and that states view dementia research as a legitimate state-level priority.
The state examples demonstrate both innovation and fragmentation. Patients in Texas benefit from a coordinated research institute, while those in California benefit from better disease tracking and research recruitment through FTD registry participation. However, patients moving between states encounter different systems and requirements. Someone diagnosed with FTD in California has their diagnosis tracked; someone with the same disease in a neighboring state without similar reporting requirements does not. Federal legislation, if enacted, could create consistency across state lines, though state-specific initiatives allow tailoring to local health needs and resources.
What Does This Legislation Mean for Patients and Families?
For someone living with dementia or caring for a family member, these legislative advances translate into potential improvements in access and quality of care within the next few years. If ASAP Act passes, a Medicare-eligible patient with memory concerns gains access to blood biomarker testing without high out-of-pocket costs. If CHANGE Act passes, clinicians will have clearer protocols for early assessment rather than ad-hoc approaches. If AADAPT Act passes, the primary care doctor involved in initial care is more likely to have current knowledge rather than outdated assumptions about dementia. The compounding effect of all three bills working together creates a more integrated early detection system.
In practical terms, consider a family that suspects dementia in a parent. Today, they often must push for specialist referrals, wait weeks for neurology appointments in some areas, pay for expensive testing, and navigate confusing terminology about biomarkers and cognitive decline. With these bills fully implemented, that same family could see the primary care doctor, receive a validated cognitive assessment, access a blood biomarker test covered by insurance, and receive referral to a specialist if needed—potentially within two visits rather than across months. This matters not just for patient outcomes but for caregiver stress and family financial burden. Early detection that leads to lifestyle modifications or clinical trial enrollment can extend the period of functional independence, directly affecting quality of life.
What Comes Next as Legislation Advances Through Congress?
The CHANGE Act’s unanimous advancement out of the Ways and Means Committee suggests a clear path toward floor consideration and potential passage, though this represents only one step. Bipartisan committee advancement often indicates broader congressional support, but recent legislative history shows that even bills with broad initial support can stall if floor time becomes constrained or if amendments prove contentious. The ASAP and AADAPT acts face similar dynamics—strong advocacy support and bipartisan sponsorship improve odds, but passage is not guaranteed until votes occur.
Beyond the immediate legislative horizon, these bills represent a shift in how policymakers view dementia: not as an inevitable consequence of aging but as a public health challenge amenable to research investment, early detection infrastructure, and workforce development. If the current bills pass, they may create momentum for additional dementia-focused legislation—perhaps funding for long-term care infrastructure, support for family caregivers, or initiatives targeting less-common dementia types. The state-level progress in Texas and California suggests that if federal legislation stalls, states will continue advancing their own policies, potentially creating a patchwork that eventually pushes Congress to establish minimum national standards. Either pathway—federal leadership or state-driven momentum building toward federal action—indicates that the legislative attention to dementia is likely to persist regardless of whether any single bill faces delays.
Conclusion
The convergence of three major bipartisan bills—CHANGE, ASAP, and AADAPT—alongside a $100 million federal funding increase and $41.5 million in CDC implementation funding demonstrates that dementia research and early detection have become bipartisan legislative priorities. These measures address different but complementary gaps: early detection protocols, Medicare coverage for blood biomarker tests, and primary care workforce training. None of these bills alone solves the dementia challenge, but together they construct a more integrated system for identifying disease earlier and equipping healthcare providers with current knowledge and resources.
If you or a family member faces dementia concerns, stay informed about the status of these bills as they move through Congress—their passage directly affects your access to early testing and specialist care. Monitor your state’s dementia initiatives as well, since state-level actions like Texas’s DPRIT and California’s FTD registry create immediate improvements even as federal legislation develops. Support from patient advocacy organizations and families continues to strengthen the case for these measures, making voice and engagement part of how dementia research priorities advance.
